Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
Adult
Aged
Biomarkers, Tumor
Brain
/ diagnostic imaging
Brain Neoplasms
/ diagnostic imaging
Cohort Studies
Contrast Media
Evaluation Studies as Topic
Female
Glioblastoma
/ diagnostic imaging
Humans
Image Enhancement
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Retrospective Studies
Survival Analysis
Tumor Burden
Glioblastoma
brain
prognostic index
segmentation
tumor
Journal
Acta radiologica (Stockholm, Sweden : 1987)
ISSN: 1600-0455
Titre abrégé: Acta Radiol
Pays: England
ID NLM: 8706123
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
pubmed:
18
9
2020
medline:
9
9
2021
entrez:
17
9
2020
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is the commonest malignant primary brain tumor and still has one of the worst prognoses among cancers in general. There is a need for non-invasive methods to predict individual prognosis in patients with GBM. To evaluate quantitative volumetric tissue assessment of enhancing tumor volume on cranial magnetic resonance imaging (MRI) as an imaging biomarker for predicting overall survival (OS) in patients with GBM. MRI scans of 49 patients with histopathologically confirmed GBM were analyzed retrospectively. Baseline contrast-enhanced (CE) MRI sequences were transferred to a segmentation-based three-dimensional quantification tool, and the enhancing tumor component was analyzed. Based on a cut-off percentage of the enhancing tumor volume (PoETV) of >84.78%, samples were dichotomized, and the OS and intracranial progression-free survival (PFS) were evaluated. Univariable and multivariable analyses, including variables such as sex, Karnofsky Performance Status score, The median OS and PFS were 16.9 and 7 months in the entire cohort, respectively. Patients with a CE tumor volume of >84.78% showed a significantly shortened OS (12.9 months) compared to those with a CE tumor volume of ≤84.78% (17.7 months) (hazard ratio [HR] 2.72; 95% confidence interval [CI] 1.22-6.03; We observed a correlation between PoETV and OS. This imaging biomarker may help predict the OS of patients with GBM.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma multiforme (GBM) is the commonest malignant primary brain tumor and still has one of the worst prognoses among cancers in general. There is a need for non-invasive methods to predict individual prognosis in patients with GBM.
PURPOSE
OBJECTIVE
To evaluate quantitative volumetric tissue assessment of enhancing tumor volume on cranial magnetic resonance imaging (MRI) as an imaging biomarker for predicting overall survival (OS) in patients with GBM.
MATERIAL AND METHODS
METHODS
MRI scans of 49 patients with histopathologically confirmed GBM were analyzed retrospectively. Baseline contrast-enhanced (CE) MRI sequences were transferred to a segmentation-based three-dimensional quantification tool, and the enhancing tumor component was analyzed. Based on a cut-off percentage of the enhancing tumor volume (PoETV) of >84.78%, samples were dichotomized, and the OS and intracranial progression-free survival (PFS) were evaluated. Univariable and multivariable analyses, including variables such as sex, Karnofsky Performance Status score,
RESULTS
RESULTS
The median OS and PFS were 16.9 and 7 months in the entire cohort, respectively. Patients with a CE tumor volume of >84.78% showed a significantly shortened OS (12.9 months) compared to those with a CE tumor volume of ≤84.78% (17.7 months) (hazard ratio [HR] 2.72; 95% confidence interval [CI] 1.22-6.03;
CONCLUSION
CONCLUSIONS
We observed a correlation between PoETV and OS. This imaging biomarker may help predict the OS of patients with GBM.
Identifiants
pubmed: 32938221
doi: 10.1177/0284185120953796
doi:
Substances chimiques
Biomarkers, Tumor
0
Contrast Media
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM